QPPV.COM

Introduction

Computerised systems have become fundamental to modern pharmacovigilance. Individual Case Safety Reports (ICSRs), literature monitoring, signal detection, aggregate reporting, electronic regulatory submissions, risk management, quality management and inspection readiness all depend upon software systems that create, process, analyse or store regulated data.

Confidence in pharmacovigilance therefore depends not only upon the competence of the personnel performing these activities but also upon confidence that the underlying computerised systems operate correctly, consistently and reliably throughout their operational lifecycle.

Computerised System Validation (CSV) provides documented evidence that a computerised system is fit for its intended use and continues to perform as expected within a controlled and maintained validated state.

Within pharmacovigilance, CSV is not merely an information technology exercise. It is an essential quality and patient safety activity. Deficiencies within computerised systems may result in delayed regulatory reporting, inaccurate safety analyses, incomplete signal detection, loss of critical safety data or failure to comply with regulatory requirements.

The objective of validation is therefore not simply regulatory compliance. Its ultimate purpose is to provide confidence that computerised systems consistently support patient safety, data integrity and scientifically reliable pharmacovigilance activities.

This article explains the principles, lifecycle, regulatory expectations and practical implementation of Computerised System Validation within pharmacovigilance. It also discusses modern concepts such as risk-based validation, Computer Software Assurance (CSA), cloud-based systems and validation of artificial intelligence technologies.

Learning Objectives

After reading this article, you should be able to:

Why Computerised System Validation Matters

Modern pharmacovigilance is almost entirely dependent upon computerised systems.

Examples include:

Failure of these systems may have significant consequences.

Examples include:

Consequently, CSV should be viewed as an integral component of pharmacovigilance governance rather than solely an information technology activity.

What Is Computerised System Validation?

Computerised System Validation (CSV) is the documented process of demonstrating that a computerised system consistently performs according to its predefined requirements and is suitable for its intended use throughout its operational lifecycle.

Three fundamental questions underpin every validation exercise.

Validation does not attempt to prove that software is completely free from defects. Such proof is rarely achievable for complex software systems.

Instead, validation provides reasonable assurance that the identified risks have been appropriately managed and that any residual risks remain acceptable within the intended regulatory context.

Accordingly, validation is fundamentally a process of generating confidence rather than attempting to eliminate every possible software defect.

Validation Is About Intended Use

One of the most important principles of Computerised System Validation is that systems are validated for their intended use rather than validated in absolute terms.

The same software application may require very different validation strategies depending upon:

For example, validating a pharmacovigilance safety database responsible for expedited reporting requires substantially greater rigour than validating a document repository used only for administrative records.

Validation should therefore begin by understanding how the organisation intends to use the system rather than simply documenting technical specifications.

Validation Is a Lifecycle Activity

Validation is not a one-time project performed immediately before implementation.

Instead, validation extends throughout the entire lifecycle of the computerised system.

The lifecycle typically includes:

Maintaining the validated state throughout this lifecycle is generally more challenging than completing the initial validation.

Consequently, modern CSV places considerable emphasis upon lifecycle management, governance and continuous assurance rather than isolated validation projects.

Scientific Foundation

Computerised System Validation is not the process of proving that software is perfect. It is the process of generating sufficient objective evidence that a computerised system remains fit for its intended use while protecting patient safety, ensuring data integrity and supporting regulatory compliance throughout its lifecycle.

Regulatory Framework for Computerised System Validation

Computerised System Validation is not governed by a single regulation. Instead, regulatory expectations arise from multiple international guidelines that collectively require regulated organisations to demonstrate that computerised systems remain suitable for their intended use, maintain data integrity and support patient safety.

Although the terminology and emphasis differ between jurisdictions, the underlying principles are remarkably consistent. Organisations should adopt a risk-based lifecycle approach, maintain documented evidence of validation activities and ensure that validated systems continue to operate within a controlled state throughout their operational lifetime.

Understanding the regulatory framework helps organisations develop validation programmes that satisfy both regulatory expectations and business requirements.

European Union Requirements

Within the European Union, pharmacovigilance systems are expected to support compliance with Good Pharmacovigilance Practices (GVP).

GVP Module I requires marketing authorisation holders to maintain quality systems that ensure pharmacovigilance activities are performed consistently and reliably. Computerised systems supporting these activities should therefore be appropriately validated and controlled.

For systems supporting manufacturing activities, Annex 11 of the EU Guidelines for Good Manufacturing Practice provides detailed expectations relating to computerised systems. Although Annex 11 is written for GMP environments, many of its principles have influenced validation practices throughout GxP disciplines, including pharmacovigilance.

United States Requirements

In the United States, computerised systems are influenced by several important regulatory documents.

Title 21 Code of Federal Regulations (21 CFR Part 11) establishes requirements for electronic records and electronic signatures.

The United States Food and Drug Administration (FDA) has also introduced Computer Software Assurance (CSA), encouraging organisations to adopt a risk-based approach that focuses testing and documentation on activities that affect patient safety, product quality and data integrity rather than producing unnecessary validation documentation.

The CSA approach does not reduce regulatory expectations. Instead, it encourages organisations to generate evidence that is meaningful, efficient and proportionate to system risk.

International Guidance

Several international publications have significantly influenced modern validation practice.

Among the most widely adopted are:

Although these documents differ in scope, they consistently promote lifecycle thinking, quality risk management and maintenance of the validated state.

Common Regulatory Themes

Across different jurisdictions and guidance documents, several recurring principles emerge.

These include:

These principles form the foundation of modern Computerised System Validation regardless of the software platform or regulatory region.

Risk-Based Computerised System Validation

Modern Computerised System Validation is fundamentally risk based.

Historically, many organisations attempted to validate every function of every computerised system with similar levels of documentation and testing. Although this approach generated extensive validation documentation, it often diverted resources towards low-risk activities while providing relatively little additional assurance for functions that directly affected patient safety or regulatory compliance.

Contemporary validation philosophy instead focuses validation effort where failure would have the greatest potential impact.

Accordingly, validation activities should be proportionate to the risks presented by the system, its intended use and the criticality of the business processes it supports.

Why a Risk-Based Approach Is Necessary

Not every computerised system presents the same level of regulatory or patient safety risk.

For example, failure of a document formatting application is unlikely to compromise patient safety directly.

In contrast, failure of a pharmacovigilance safety database responsible for expedited regulatory reporting could result in delayed reporting of serious adverse reactions, incomplete safety data or incorrect regulatory submissions.

Applying identical validation effort to both systems would therefore represent an inefficient use of resources.

Risk-based validation allows organisations to concentrate testing, review and documentation on those areas where confidence is most important.

What Determines Validation Effort?

The extent of validation should be influenced by several factors.

These include:

Validation effort should increase as the potential consequences of system failure increase.

Patient Safety as the Primary Consideration

The ultimate purpose of pharmacovigilance is protection of patients.

Consequently, validation decisions should always consider how system failure might affect patient safety.

Examples include failures that could:

Systems supporting these activities generally require more rigorous validation than systems supporting purely administrative functions.

Data Integrity and Regulatory Compliance

In addition to patient safety, organisations should evaluate the effect of system failure on data integrity and regulatory compliance.

Reliable pharmacovigilance depends upon complete, accurate, consistent and traceable safety data.

Validation therefore seeks to provide confidence that computerised systems preserve:

Protection of data integrity remains a central expectation across international regulatory guidance.

GAMP 5 and the Evolution of Validation

The publication of GAMP 5, and subsequently GAMP 5 Second Edition, reinforced the principle that validation should be science based and risk based.

Rather than prescribing identical validation activities for every system, GAMP encourages organisations to understand:

This philosophy has significantly influenced modern validation practice across multiple GxP disciplines, including pharmacovigilance.

Risk-Based Validation Does Not Mean Less Validation

A common misconception is that risk-based validation reduces validation activities.

This is incorrect.

Instead, risk-based validation seeks to optimise validation effort.

Low-risk functions should not receive disproportionate testing simply because they exist.

Conversely, high-risk functions should receive sufficient scrutiny to provide confidence that they perform reliably under normal and reasonably foreseeable operating conditions.

The objective is therefore better validation rather than more validation.

Scientific Foundation

A risk-based approach recognises that the objective of Computerised System Validation is not to produce the largest validation package. It is to generate sufficient objective evidence that the functions most important to patient safety, data integrity and regulatory compliance perform reliably throughout the system lifecycle.

The Computerised System Validation Lifecycle

Computerised System Validation is a lifecycle activity rather than a single project performed immediately before a system is placed into production.

Confidence in a computerised system is established progressively throughout its lifecycle, beginning before the system is acquired and continuing until the system is retired.

Each stage contributes objective evidence that the system remains suitable for its intended use while continuing to protect patient safety, maintain data integrity and support regulatory compliance.

Although organisations may use different terminology or documentation, modern validation programmes generally follow the same lifecycle.

Planning and System Selection

Validation begins long before software installation.

Organisations should first determine:

Selection of an appropriate supplier is equally important.

Supplier assessment should consider factors such as:

Early planning establishes the foundation upon which all subsequent validation activities depend.

Requirements Definition

Once the system has been selected, the organisation should define what the system is expected to achieve.

Requirements should describe business needs rather than technical implementation.

Examples include:

Well-defined requirements provide the benchmark against which validation activities are performed.

System Configuration and Implementation

Following definition of requirements, the system is configured, developed or implemented according to organisational needs.

Activities during this stage may include:

Implementation should remain controlled through documented change management processes.

Verification and Testing

Testing provides objective evidence that the implemented system performs according to predefined requirements.

The scope and depth of testing should reflect the level of risk associated with the system and its intended use.

Testing typically evaluates:

The objective is not to demonstrate perfection but to generate sufficient confidence that the validated system performs reliably.

Release and Operational Use

Following successful completion of validation activities, the organisation may approve the system for operational use.

Approval should confirm that:

Only after these activities have been completed should the system enter routine operational use.

Maintaining the Validated State

Validation does not end when the system becomes operational.

Throughout its lifecycle, organisations should maintain confidence that the validated state continues to exist despite:

Maintaining the validated state requires ongoing governance, periodic review, effective change control and continued monitoring of system performance.

System Retirement

Eventually, every computerised system reaches the end of its operational life.

Retirement should be managed in a controlled manner to ensure:

Retirement therefore represents the final phase of validation rather than the end of organisational responsibility.

Validation Is Continuous Assurance

Viewed collectively, these lifecycle stages demonstrate an important principle.

Validation should not be regarded as a collection of independent documents.

Rather, it is a continuous process of generating and maintaining confidence that a computerised system remains fit for its intended use throughout its operational lifetime.

This lifecycle philosophy underpins modern guidance including GAMP 5 Second Edition and the FDA's Computer Software Assurance approach, both of which emphasise continuous assurance over documentation generated solely to satisfy regulatory expectations.

Scientific Foundation

The validated state is not achieved when the final validation report is approved. It is maintained through effective governance, risk management, change control and continuous assurance throughout the operational life of the computerised system.

Validation Documentation

Computerised System Validation is supported by documented evidence demonstrating that validation activities have been planned, performed, reviewed and approved appropriately.

Documentation should not exist merely to satisfy regulatory expectations. Instead, each document should contribute objective evidence supporting confidence that the computerised system remains fit for its intended use.

Modern validation programmes increasingly emphasise documentation that provides meaningful assurance rather than documentation produced solely to complete a validation package.

Although document names may differ between organisations, most validation programmes contain similar core deliverables.

Validation Planning Documents

Validation begins by defining how validation activities will be performed.

Planning documentation typically describes:

These documents establish the framework governing the remainder of the validation programme.

Requirements Documentation

Requirements documentation describes what the system must achieve.

Examples include:

Requirements should describe organisational needs rather than technical implementation.

Well-defined requirements provide the foundation upon which configuration, testing and acceptance activities are based.

Design and Configuration Documentation

Following approval of requirements, documentation should describe how the system has been configured or developed to satisfy those requirements.

Depending upon the implementation, documentation may include:

The depth of documentation should remain proportionate to system complexity and risk.

Verification Documentation

Verification documentation demonstrates that implemented functionality performs according to approved requirements.

Typical examples include documentation relating to:

Verification documentation should provide objective evidence that critical functions operate consistently and reliably.

Traceability Documentation

One of the defining characteristics of a well-managed validation programme is traceability.

Organisations should be able to demonstrate clear relationships between:

Effective traceability allows reviewers and inspectors to determine whether every important requirement has been evaluated appropriately.

Operational Documentation

Validation continues after implementation.

Operational documentation supports maintenance of the validated state throughout the system lifecycle.

Examples include:

These records demonstrate continued control of the validated system.

Documentation Should Demonstrate Assurance

One of the major changes introduced by modern validation philosophies is the recognition that documentation is valuable only when it demonstrates meaningful assurance.

Producing large numbers of documents that add little understanding of system performance does not improve validation.

Instead, documentation should be:

Well-designed documentation explains why confidence in the computerised system is justified rather than merely recording that validation activities occurred.

Scientific Foundation

Validation documentation is not the objective of Computerised System Validation. It is the documented evidence that supports confidence that the system performs reliably, protects patient safety, preserves data integrity and remains fit for its intended use.

Computerised Systems Used in Pharmacovigilance

Modern pharmacovigilance is supported by an ecosystem of interconnected computerised systems rather than a single application.

Each system performs a specific function within the pharmacovigilance process and may exchange information with numerous internal and external systems. Consequently, validation should consider not only the individual application but also the interfaces, data flows and business processes that depend upon it.

The validation approach should always be proportionate to the intended use, regulatory significance and potential impact of system failure.

Safety Databases

Safety databases form the core of most pharmacovigilance systems.

Typical functions include:

Failure of a safety database may affect regulatory reporting timelines, case quality, aggregate analyses and inspection readiness.

Accordingly, these systems usually require comprehensive validation and ongoing change control.

Electronic Reporting Systems

Many organisations use dedicated systems or gateways to exchange regulatory information electronically.

Examples include:

Validation should demonstrate reliable generation, transmission, receipt and acknowledgement of electronic regulatory submissions.

Interface failures should be detectable, documented and appropriately managed.

Signal Management Systems

Signal management increasingly relies upon specialised software capable of integrating multiple sources of safety information.

Typical functionality includes:

Validation should provide confidence that signal management activities remain complete, traceable and reproducible throughout the signal lifecycle.

Literature Monitoring Systems

Literature monitoring systems support identification, screening and evaluation of published scientific literature.

Depending upon organisational processes, these systems may perform:

Validation should demonstrate that searches, workflows and documentation remain reliable and reproducible.

Quality Management Systems

Quality Management Systems (QMS) support governance of pharmacovigilance activities.

Typical functions include:

Although these systems may not directly process safety data, failure may compromise overall pharmacovigilance governance and inspection readiness.

Supporting Systems

Many additional computerised systems indirectly support pharmacovigilance activities.

Examples include:

The extent of validation should reflect the significance of each system within the regulated business process.

Interfaces Between Systems

Modern pharmacovigilance rarely depends upon isolated applications.

Instead, information frequently flows between multiple computerised systems.

Examples include:

Validation should therefore include interfaces where failure could compromise data integrity, completeness or regulatory compliance.

Successful validation of individual systems does not automatically demonstrate reliable operation of integrated workflows.

Cloud-Based and Software-as-a-Service Systems

Increasingly, pharmacovigilance applications are provided through cloud-based or Software-as-a-Service (SaaS) platforms.

Although responsibility for infrastructure may reside with the service provider, responsibility for ensuring that the system remains fit for its intended use continues to rest with the regulated organisation.

Consequently, organisations should establish appropriate governance for:

Use of cloud technologies changes the validation approach but does not remove validation responsibilities.

Scientific Foundation

Computerised systems should be validated according to the regulated business processes they support rather than the technology on which they are built. The greater the potential impact of system failure on patient safety, data integrity or regulatory compliance, the greater the assurance required.

Inspection and Audit Perspective

Computerised System Validation is routinely reviewed during pharmacovigilance inspections and quality audits because validated computerised systems underpin the reliability of regulated pharmacovigilance activities.

Inspectors generally do not attempt to determine whether every individual validation document has been produced. Instead, they seek objective evidence that the organisation understands its computerised systems, has appropriately managed validation risks and maintains those systems in a validated state throughout their operational lifecycle.

Accordingly, inspection findings frequently relate to weaknesses in governance rather than isolated documentation deficiencies.

What Inspectors Want to See

During an inspection, regulators typically seek confidence that:

The objective is to determine whether the organisation can consistently rely upon the systems supporting its pharmacovigilance activities.

Demonstrating the Validated State

Inspectors frequently focus on whether validation represents an ongoing management process rather than a historical implementation project.

Evidence commonly reviewed includes:

Collectively, these documents demonstrate that confidence in the system has been maintained over time.

Data Integrity

Data integrity remains one of the central themes of regulatory inspections.

Inspectors expect organisations to demonstrate that pharmacovigilance data remain:

Validation should therefore demonstrate not only functional correctness but also appropriate controls protecting the integrity of regulated data.

Governance and Oversight

Computerised System Validation should operate within the organisation's Pharmaceutical Quality System and Pharmacovigilance Quality System.

Governance should clearly define responsibilities for:

Effective governance ensures that validation responsibilities remain clear throughout the lifecycle of the system.

Supplier Oversight

Many pharmacovigilance systems are developed, hosted or supported by third-party suppliers.

Although suppliers perform many operational activities, regulatory responsibility for the validated state remains with the regulated organisation.

Accordingly, organisations should maintain appropriate oversight of supplier performance through activities such as:

Delegation of operational activities does not transfer regulatory accountability.

Inspection Readiness

Inspection readiness should not be viewed as a separate validation activity performed immediately before an inspection.

Instead, organisations should maintain validation documentation, governance processes and evidence in a state of continuous readiness.

This approach enables organisations to demonstrate confidence in their computerised systems at any point during the system lifecycle rather than preparing evidence retrospectively.

Inspection Insight

Inspectors are rarely interested in the size of a validation package. They are interested in whether the organisation can demonstrate, through objective evidence, that its computerised systems remain fit for their intended use and continue to support reliable pharmacovigilance activities.

Common Mistakes in Computerised System Validation

Computerised System Validation deficiencies rarely arise because organisations are unaware of regulatory requirements. More commonly, they result from inadequate planning, poor governance, incomplete risk assessment or failure to maintain the validated state throughout the system lifecycle.

Understanding these recurring deficiencies helps organisations design validation programmes that are scientifically robust, proportionate and inspection ready.

Validation Strategy Mistakes

One of the most common mistakes is treating validation as a documentation exercise rather than a quality assurance activity.

Examples include:

These approaches frequently increase documentation without increasing confidence in system performance.

Requirements and Testing Mistakes

Many validation deficiencies originate during requirements definition.

Examples include:

Testing cannot compensate for poorly defined requirements.

Consequently, deficiencies introduced during the planning phase often remain throughout the validation lifecycle.

Governance Mistakes

Validation depends upon effective governance.

Common governance deficiencies include:

These weaknesses frequently result in systems gradually drifting away from their validated state.

Operational Mistakes

Maintaining validation throughout routine operation is often more challenging than initial implementation.

Examples of operational deficiencies include:

These issues may compromise confidence in system reliability despite successful initial validation.

Documentation Mistakes

Modern regulatory guidance encourages organisations to produce documentation that demonstrates meaningful assurance.

However, organisations sometimes generate extensive documentation that contributes little objective evidence.

Common deficiencies include:

Well-structured documentation should improve understanding rather than increase administrative complexity.

Inspection Findings

Inspection observations frequently relate to broader quality system weaknesses rather than isolated validation documents.

Examples include:

These findings often indicate systemic governance issues rather than isolated technical failures.

Emerging Challenges

Modern pharmacovigilance introduces validation challenges that extend beyond traditional client-server applications.

Increasing attention is being given to:

These technologies require organisations to adapt traditional validation approaches while continuing to demonstrate confidence in system performance, data integrity and regulatory compliance.

Scientific Foundation

Effective Computerised System Validation is not measured by the number of validation documents produced. It is measured by the organisation's ability to demonstrate continued confidence that regulated computerised systems remain fit for their intended use throughout their operational lifecycle.

How an Experienced CSV Lead and QPPV Think

Experienced validation professionals recognise that Computerised System Validation is fundamentally a process of building confidence rather than producing documentation.

When reviewing a computerised system, they rarely begin by asking whether a Validation Plan, User Requirements Specification or Validation Summary Report exists.

Instead, they ask whether the organisation can demonstrate that the system continues to perform reliably while supporting patient safety, protecting data integrity and complying with regulatory requirements.

Documentation provides evidence of this confidence, but documentation alone does not create confidence.

They Think in Terms of Business Processes

Experienced CSV professionals understand that software does not exist in isolation.

Instead of evaluating individual screens or software functions independently, they first consider the regulated business process supported by the system.

Typical questions include:

The business process therefore determines the validation strategy rather than the software itself.

They Think in Terms of Risk

Experienced validation professionals recognise that not every function deserves identical attention.

Instead, they continuously ask:

Their objective is to direct validation effort where it provides the greatest assurance rather than where it produces the greatest quantity of documentation.

They Think Across the Entire Lifecycle

Experienced CSV Leads understand that successful implementation is only the beginning.

They continually evaluate whether the validated state is being maintained through:

Validation is therefore viewed as a continuous operational responsibility rather than a project with a defined completion date.

They Think Like Inspectors

Experienced professionals regularly challenge their own systems using the perspective of an inspector.

Typical questions include:

This mindset promotes continuous inspection readiness rather than reactive preparation before regulatory inspections.

They Balance Compliance and Practicality

Experienced CSV professionals understand that regulatory compliance and operational efficiency are not competing objectives.

Overly complex validation programmes consume resources without necessarily improving assurance.

Conversely, insufficient validation may expose patients, organisations and regulators to unnecessary risk.

Professional judgement lies in selecting validation activities that are scientifically justified, proportionate to risk and capable of providing meaningful confidence.

Professional Reflection

Experienced validation professionals do not measure success by the number of completed validation documents. They measure success by the confidence with which the organisation can rely upon its computerised systems to support safe, accurate and compliant pharmacovigilance activities throughout their lifecycle.

Key Takeaways

Computerised System Validation provides documented evidence that regulated computerised systems remain fit for their intended use throughout their operational lifecycle.

Modern validation is founded upon lifecycle management, quality risk management and maintenance of the validated state rather than documentation generated solely for regulatory compliance.

Successful validation programmes focus on patient safety, data integrity, regulatory compliance and business process reliability while applying validation effort in proportion to system risk.

Ultimately, Computerised System Validation supports confidence in pharmacovigilance activities by ensuring that the systems responsible for generating, processing, analysing and reporting safety information remain reliable throughout their operational life.

Continue Reading

Computerised System Validation

References

European Union Legislation and Guidance

  1. European Commission. Commission Implementing Regulation (EU) No 520/2012 on the performance of pharmacovigilance activities.

  2. Directive 2001/83/EC relating to medicinal products for human use.

  3. Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products.

  4. European Medicines Agency. Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and their Quality Systems.

  5. European Commission. EudraLex Volume 4. EU Guidelines for Good Manufacturing Practice. Annex 11: Computerised Systems.

United States Guidance

  1. U.S. Food and Drug Administration. 21 CFR Part 11 – Electronic Records; Electronic Signatures.

  2. U.S. Food and Drug Administration. Computer Software Assurance for Production and Quality System Software. Guidance for Industry.

  3. U.S. Food and Drug Administration. General Principles of Software Validation.

  4. U.S. Food and Drug Administration. Data Integrity and Compliance with Drug CGMP.

International Standards and Guidance

  1. ISPE. GAMP® 5 Second Edition: A Risk-Based Approach to Compliant GxP Computerized Systems.

  2. ICH Q9(R1): Quality Risk Management.

  3. PIC/S. Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments.

  4. World Health Organization. Guidance on Good Data and Record Management Practices.

Data Integrity

  1. MHRA. GxP Data Integrity Guidance and Definitions.

  2. WHO. Annex: Good Data and Record Management Practices.

  3. ALCOA and ALCOA+ principles as described in international regulatory guidance.

Computerised Systems and Quality

  1. ISPE Baseline Guides relating to GxP Computerised Systems.

  2. ISPE Good Practice Guides relevant to Computerised System Validation.

  3. ISPE publications relating to cloud computing and regulated systems.

  4. ISPE publications relating to software lifecycle management.

Scientific Literature

  1. Articles describing lifecycle validation methodologies.

  2. Publications on quality risk management for regulated computerised systems.

  3. Peer-reviewed literature on validation of safety databases.

  4. Publications relating to validation governance.

  5. Scientific literature describing validation of cloud-based GxP systems.

  6. Publications relating to validation of Software-as-a-Service (SaaS) platforms.

  7. Peer-reviewed publications relating to electronic records and electronic signatures.

  8. Literature describing validation approaches for artificial intelligence in regulated healthcare environments.

  9. Publications on validation of machine learning systems in healthcare.

  10. Recent scientific publications relating to Computer Software Assurance and modern validation methodologies.